RET-rearranged non-small-cell lung cancer and therapeutic implications.

2019-12

Loh, Zoe

Mitchell, Paul L R

John, Thomas

Arulananda, Surein

RET rearrangement

genomic profiling

non-small-cell lung cancer

tyrosine kinase inhibitor

vandetanib

Journal Article

0000-0002-9215-1441

0000-0002-5636-6381

10.1111/imj.14654

First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.

link

Internal Medicine Journal 2019; 49(12): 1541-1545

Internal Medicine Journal